Ampio Pharma Stock Price, News & Analysis

Ampio Pharmaceuticals (AMPE) announced receipt of FDA responses regarding the AP-013 trial results. The FDA disagreed with the proposed switch from the intent-to-treat (ITT) to modified intent-to-treat (mITT) analysis, citing it as a significant protocol change. Furthermore, the FDA stated that AP-013 cannot serve as a second pivotal trial for Ampion due to these changes. CEO Mike Martino expressed disappointment but indicated potential pathways to salvage the trial. He suggested that a new Phase 3 trial may be the best option moving forward for gaining BLA approval.

Ampio Pharmaceuticals (AMPE) reported a net loss of $6.2 million for Q4 2021, up from $4.6 million in Q4 2020, and an annual net loss of $17.1 million compared to $15.9 million in 2020. Despite this, the company secured $34 million in cash, expected to fund operations into H2 2023. Positive Phase 3 data for its osteoarthritis treatment, Ampion, was reported, with significant reductions in pain. The company's leadership has been strengthened with key appointments, and further clarity from the FDA is anticipated regarding the Ampion Biologics Licensing Application.

Ampio Pharmaceuticals, Inc. (AMPE) will host its fourth quarter earnings and business update call on March 29, 2022, at 4:30 PM EST. The call aims to provide insights into the company's financial performance and future direction. Ampio focuses on immunomodulatory therapies for osteoarthritis pain, with its lead product, Ampion™, backed by a robust patent portfolio and potential FDA market exclusivity through the Biologics Price Competition and Innovation Act. Investors are encouraged to join the call for detailed updates.

Ampio Pharmaceuticals, Inc. (AMPE) will attend the 34th Annual ROTH Conference from March 13-15, 2022, in Laguna Niguel, California. CEO Mike Martino will engage in one-on-one meetings with investors and participate in a fireside chat on March 15 at 4:30pm ET. The conference hosts nearly 550 companies and over 5,100 attendees, focusing on small-cap firms across various sectors.

Ampio's lead drug, Ampion™, targets inflammatory conditions and may secure 12-year FDA market exclusivity upon approval.

Ampio Pharmaceuticals, Inc. (AMPE) announced promising results from its Phase 3 AP-013 study of Ampion™ for treating severe osteoarthritis of the knee. The study showed a statistically significant pain reduction (p=0.042) in the modified Intent-to-Treat population (n=618) and notable improvements in function (p=0.027) compared to saline control. These results corroborate findings from the earlier AP-003-A trial. The company has engaged with the FDA regarding next steps, anticipating further clarity on the data by mid-2022.

Ampio Pharmaceuticals (NYSE American: AMPE) announced a webinar and conference call on March 2, 2022, at 4:30 PM EST, to update on clinical progress regarding osteoarthritis of the knee. Interested participants can join via the provided webinar link. The company focuses on developing immunomodulatory therapies for inflammatory conditions, with its lead drug, Ampion™, aiming for FDA approval. Forward-looking statements in the press release discuss potential future plans and risks.

Ampio Pharmaceuticals (NYSE American: AMPE) announced the appointment of Elizabeth Varki Jobes, Esq. to its Board of Directors, expanding the board from seven to eight members. This strategic addition aims to enhance the company's governance as it prepares for discussions with the FDA regarding a Biological License Application (BLA) submission for its lead drug, Ampion. Jobes brings nearly 30 years of legal and compliance expertise from various biopharmaceutical companies, positioning Ampio favorably in its efforts to advance immunology-based therapies.

Ampio Pharmaceuticals (NYSE: AMPE) announced its participation in the H.C. Wainwright Bioconnect Virtual Conference from January 10-13, 2022. CEO Michael Martino will present a corporate overview starting at 7:00 a.m. ET on January 10, accessible via the event website. Ampio focuses on immunology-based therapies for inflammatory conditions, with its lead drug Ampion supported by a robust patent portfolio valid until 2037.

Ampio Pharmaceuticals (AMPE) announced a successful $22.5 million registered direct offering, providing approximately $21 million in net proceeds. With expectations to end 2021 with $13 million in cash, the company now holds about $34 million to support its operational plans for over a year. CEO Mike Martino highlighted the potential for Ampio to submit a Biologics License Application (BLA) for its lead drug, Ampion, and pursue partnerships for further development. The company is focused on achieving targeted FDA agreements and securing strategic collaborations in 2022.